Adimab enters 2 antibody discovery deals

04/23/2012 | Pharmaceutical Business Review Online

Adimab signed an agreement to discover fully human antibodies against up to two targets chosen by Gilead Sciences. In a separate deal, the company agreed to use its discovery platform to find bispecific antibodies that bind two targets chosen by an unnamed partner. Adimab could receive milestone payments and royalties from each partner.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID